Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
u-ReMeta Exosome is an exosome and extracellular vesicle product developed by MetaTech Biomed for applications in regenerative medicine. Exosomes are small, membrane-bound vesicles secreted by cells that carry a cargo of proteins, lipids, and nucleic acids, facilitating intercellular communication and paracrine signaling. While specific clinical indications are not detailed in the company's public portfolio, the product is positioned within their regenerative medicine and cell therapy services, likely aimed at tissue repair or anti-aging through the delivery of bioactive factors. It is distinguished from the company's i-ReMeta product, which is specifically derived from induced pluripotent stem cells (iPSCs).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on u-ReMeta Exosome.